REPOSITIONING INTELLIGENCE — EVIDENCE REPORT
============================================
Generated: Nov 12, 2026, 11:53 PM UTC

DISCLAIMER: This report is for research and informational use only.
It is NOT medical advice, diagnosis, or treatment guidance.

DRUG–DISEASE PAIRING
--------------------
Drug:     Levothyroxine (Synthroid)
Disease:  Hypothyroidism
Target:   Thyroid hormone receptor

EVIDENCE GRADE: Approved
Confidence Score: 98%
Evidence Level: Level 1 (guideline-endorsed standard of care)


MECHANISM
---------
Exogenous T4 restores normal thyroid hormone levels and metabolic homeostasis.

OUTCOMES
--------
Normalization of TSH and symptom improvement; decades of clinical use.

AI SUMMARY (generated March 15, 2026)
-----------
Levothyroxine is the established first-line therapy for hypothyroidism with FDA-approved labeling, ATA/AACE guideline endorsement, and extensive long-term safety data. This is primary-use evidence rather than repurposing, but represents gold-standard drug–disease pairing.

KNOWN RISKS
-----------
• Overtreatment causing thyrotoxicosis
• Cardiac arrhythmias if overdosed
• Bone loss with supraphysiologic doses
• Drug–food interactions (calcium, iron)

CITATIONS
---------
[PUBMED] 23846913: ATA guidelines for hypothyroidism
  https://pubmed.ncbi.nlm.nih.gov/23846913/

[FDA] 021402: Synthroid (levothyroxine) FDA label
  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021402

PUBMED IDs: 23846913
CLINICAL TRIAL IDs: None

LAST VERIFIED: July 1, 2026
LAST UPDATED:  July 1, 2026
REVIEW STAGE:  published

---
Repositioning Intelligence Platform · Research Mode